Revelation Biosciences Inc (REVB) Stock Price, Quote & News

Company Profile

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 800 3717

Website: www.revbiosciences.com

Address:

4660 La Jolla Village Drive, Suite 100, San Diego, United States

durocali Aug. 20 at 8:02 PM

$REVB net cash on balance sheet is 2.5x the market cap. does the market believe this is a totally failed company with no value to be derived in the future?

0 · Reply

Schizoo Aug. 20 at 7:02 PM

$REVB low float.. high short.. hold..🤌😘

1 · Reply

MoneyMacG Aug. 20 at 6:40 PM

$REVB $GMEX $GVH $NVNI $AUUD store

0 · Reply

BioTuesdays Aug. 19 at 6:35 PM

$REVB has announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design TITAN study for evaluating Gemini in patients with acute kidney injury (AKI). https://biotuesdays.com/2026/08/19/revelation-selects-avance-clinical-as-cro-for-titan-study/

0 · Reply

Schizoo Aug. 19 at 3:12 PM

$REVB give me 3$ and im happy.

1 · Reply

kshonstocks Aug. 19 at 2:45 PM

$REVB on the off the bottom scans today

0 · Reply

Schizoo Aug. 19 at 2:25 PM

$REVB run today?

0 · Reply

ShangVXO Aug. 19 at 8:08 AM

Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $MOBX and $REVB got my attention

0 · Reply

Schizoo Aug. 17 at 5:28 PM

$REVB run it back to 3$

0 · Reply

Schizoo Aug. 17 at 3:38 PM

$REVB uptrend from a strong bottom..

0 · Reply

Revelation Biosciences selects Avance Clinical as CRO for Phase 2/3 Titan Study

Aug 19, 2026, 9:00 AM EDT - 5 days ago

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

Aug 6, 2026, 4:15 PM EDT - 18 days ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

Aug 6, 2026, 7:00 AM EDT - 18 days ago

Revelation Biosciences Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 18 days ago

Revelation Biosciences Earnings release: Q2 2026

2026-08-03T13:15:35.000Z - 21 days ago

Revelation Biosciences announces results from market assessment for Gemini

Aug 3, 2026, 9:00 AM EDT - 21 days ago

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

Jul 21, 2026, 4:05 PM EDT - 4 weeks ago

Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 10, 2026, 4:05 PM EDT - 6 weeks ago

Revelation Biosciences Announces Adoption of Stockholder Rights Plan

Jun 16, 2026, 1:07 AM EDT - 2 months ago

Revelation Biosciences Transcript: Transcript

Jun 12, 2026, 4:32 AM EDT - 2 months ago

Revelation Biosciences Earnings release

Jun 12, 2026, 4:23 AM EDT - 2 months ago

Revelation Biosciences Earnings release

2026-06-01T13:56:20.000Z - 3 months ago

Revelation Biosciences adds two new members to AKI Advisory Board

Jun 1, 2026, 9:00 AM EDT - 3 months ago

Revelation Biosciences Expands Acute Kidney Injury Advisory Board

2026-05-11T13:48:22.000Z - 3 months ago

Revelation Biosciences reports FY25 EPS ($14.35) vs ($1,052.16) last year

May 11, 2026, 9:00 AM EDT - 3 months ago

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

May 7, 2026, 4:15 PM EDT - 3 months ago

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

2026-04-06T13:18:58.000Z - 5 months ago

Revelation Biosciences announces formation of AKI advisory board

Apr 6, 2026, 9:00 AM EDT - 5 months ago

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

2026-03-30T19:56:44.000Z - 5 months ago

Revelation Gemini data show ‘broad effect,’ says Roth Capital

2026-03-30T13:21:15.000Z - 5 months ago

Revelation Biosciences presents additional data from Prime Clinical Study

Mar 30, 2026, 9:00 AM EDT - 5 months ago

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

Mar 24, 2026, 9:00 AM EDT - 5 months ago

REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

Mar 19, 2026, 9:00 AM EDT - 5 months ago

Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

Mar 1, 2026, 7:00 AM EST - 6 months ago

Revelation Biosciences Slides: Corporate presentation

2026-02-27T13:39:33.000Z - 6 months ago

Revelation Biosciences price target lowered to $16 from $20 at Roth Capital

Feb 26, 2026, 4:15 PM EST - 6 months ago

Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025

2026-01-30T21:10:32.000Z - 7 months ago

Revelation Biosciences files to sell 4.27M shares of common stock for holders

2026-01-28T00:50:09.000Z - 7 months ago

Revelation Biosciences Inc trading halted, news pending

2026-01-26T15:01:09.000Z - 7 months ago

Revelation Biosciences announces 1-for-4 reverse stock split

Jan 26, 2026, 9:55 AM EST - 7 months ago

Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026

Jan 23, 2026, 2:10 PM EST - 7 months ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds

2026-01-21T13:51:28.000Z - 7 months ago

Revelation reaches agreement with FDA on Gemini approval pathway

Jan 21, 2026, 8:30 AM EST - 7 months ago

Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI

Jan 14, 2026, 9:00 AM EST - 7 months ago

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)

Jan 12, 2026, 5:00 PM EST - 7 months ago

Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-01-07T14:17:33.000Z - 8 months ago

Revelation Biosciences initiates GMP manufacturing of GEMINI

Jan 7, 2026, 9:00 AM EST - 8 months ago

Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development

2025-12-01T14:15:23.000Z - 9 months ago

Revelation Biosciences reaches quorum for Dec. 3 special meeting

Dec 1, 2025, 9:00 AM EST - 9 months ago

Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting

2025-11-20T14:15:40.000Z - 9 months ago

Revelation Biosciences on track for end-of-phase 1 meeting later this year

Nov 20, 2025, 9:00 AM EST - 9 months ago

Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year

Nov 6, 2025, 4:15 PM EST - 10 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025

2025-10-29T13:15:56.000Z - 10 months ago

Revelation Biosciences announces cancellation of Special Meeting

Oct 29, 2025, 9:00 AM EDT - 10 months ago

Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date

Oct 15, 2025, 5:00 PM EDT - 11 months ago

Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025

2025-09-16T21:20:13.000Z - 1 year ago

Revelation Biosciences files to sell 13.07M shares of common stock for holders

2025-09-11T12:40:32.000Z - 1 year ago

Revelation Biosciences announces exercise of warrants for $9.6M in proceeds

Sep 11, 2025, 8:30 AM EDT - 1 year ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

2025-09-10T11:30:36.000Z - 1 year ago

Revelation Biosciences announces webcast to review Phase 1b PRIME data

Sep 10, 2025, 7:20 AM EDT - 1 year ago

Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

Sep 9, 2025, 4:55 PM EDT - 1 year ago

Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

2025-09-09T12:35:01.000Z - 1 year ago

Revelation Biosciences announces topline results from PRIME study

Sep 9, 2025, 8:00 AM EDT - 1 year ago

Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

Aug 8, 2025, 6:30 AM EDT - 1 year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

Jul 24, 2025, 9:00 AM EDT - 1 year ago

Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

Jul 16, 2025, 9:00 AM EDT - 1 year ago

0 · Reply

Schizoo Aug. 20 at 7:02 PM

$REVB low float.. high short.. hold..🤌😘

1 · Reply

MoneyMacG Aug. 20 at 6:40 PM

$REVB $GMEX $GVH $NVNI $AUUD store

0 · Reply

BioTuesdays Aug. 19 at 6:35 PM

0 · Reply

Schizoo Aug. 19 at 3:12 PM

$REVB give me 3$ and im happy.

1 · Reply

kshonstocks Aug. 19 at 2:45 PM

$REVB on the off the bottom scans today

0 · Reply

Schizoo Aug. 19 at 2:25 PM

$REVB run today?

0 · Reply

ShangVXO Aug. 19 at 8:08 AM

0 · Reply

Schizoo Aug. 17 at 5:28 PM

$REVB run it back to 3$

0 · Reply

Schizoo Aug. 17 at 3:38 PM

$REVB uptrend from a strong bottom..

0 · Reply

Schizoo Aug. 14 at 7:51 PM

$REVB oversoold.

0 · Reply

Schizoo Aug. 14 at 7:32 PM

$REVB swiiiiing

0 · Reply

ZacksSCR Aug. 7 at 4:15 PM

$REVB Approaching a Critical Inflection Point https://buff.ly/TpMv2lR

0 · Reply

soroh11 Aug. 6 at 10:15 PM

$REVB This should be delisted. They scam and take your money. Do a reverse split & repeat.

1 · Reply

7traderja Jul. 20 at 12:41 PM

$REVB I have only a 1000 shares at an average of $1.35. What’s causing the move recently?

0 · Reply

Suzzio Jul. 17 at 7:23 PM

$REVB k

0 · Reply

alien7180 Jul. 17 at 4:38 PM

$REVB https://www.fiercebiotech.com/biotech/dimerix-snaps-missions-stalled-phase-2-ready-kidney-disease-candidate-5m-upfront

0 · Reply

qlox Jun. 30 at 10:17 PM

$REVB REVB 2 to 250 3.72 Vote Approved

0 · Reply

qlox Jun. 30 at 10:16 PM

$REVB 1:125 reverse split coming

1 · Reply

apache007 Jun. 30 at 9:04 PM

$REVB date for delist this? please

0 · Reply

Market Cap	4.34M
Revenue (ttm)	0.00
Net Income (ttm)	-8.91M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	49,644
Avg Vol	43,404
Day's Range	N/A - N/A
Shares Out	3.98M
Stochastic %K	34%
Beta	-0.15
Analysts	Strong Sell
Price Target	$17.75